The Effect of Prone Position Drainage on the Efficacy of Severe Pneumonia,a Multicenter Randomized Controlled Trial

Overview

Enrollment criteria and clinical data collection: follow the principles of medical ethics, the development of inclusion and exclusion criteria, Select all eligible patients with severe pneumonia(SP) who were admitted to the hospital during the study date.The diagnostic criteria we will use for SP are based on the Infectious Diseases Society of America/American Thoracic Society guidelines.Primary outcome measures:a.CURB-65 Score for Pneumonia Severity;b.The changes in inflammation and coagulation indicators: C-reactive protein, procalcitonin, and d-dimer;c.Chest x-ray changes;d.Mortality rate after 28 days;e.The time of mechanical ventilation, total duration of ICU stay, hospitalization, and antibiotic use;f.The time of bacterial cultures becoming negative;g.Daily sputum drainage.The aim of this study is to evaluate the anti-infective effectiveness and safety of prone position drainage compared with supine position on SP treatment.

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Single (Participant)
  • Study Primary Completion Date: April 1, 2021

Detailed Description

Severe pneumonia (SP) is a major complication of respiratory system diseases that is associated with high mortality and morbidity. If not treated correctly, it may rapidly lead to sepsis and multiple organ dysfunction syndrome. Randomized, controlled trials have confirmed that oxygenation is significantly better when patients are in the prone position than when they are in the supine position.But whether prone drainage is beneficial for rapid infection control on SP treatment has not been researched.The aim of this study is to evaluate the anti-infective effectiveness and safety of prone position drainage compared with supine position on SP treatment. Using a central randomization system, participants will be randomized (1:1) into groups receiving either placed in prone position or in supine position (within 24 h of diagnosis of SP) for 5-7 days with a 28-day follow-up. Patients assigned to the prone group had to be turned within the first hour following randomization. They were placed in prone position for at least 16 consecutive hours. The patients enrolled in this study should meet the diagnostic and inclusion criteria and provide written informed consent. Diagnostic criteria The diagnostic criteria we will use for SP are based on the Infectious Diseases Society of America/American Thoracic Society guidelines. The inclusion criteria are as follows: 1.Age ≥18 years and ≤75 years, male or female;2.Weight ≥40 kg and ≤100 kg;3.Meet the diagnostic criteria for SP;4.Need invasive mechanical ventilation;5.Provide signed informed consent Non-inclusion criteria: 1. Contraindication for prone positioning a. Intracranial pressure >30 mm Hg or cerebral perfusion pressure <60 mmHg;b. Massive hemoptysis requiring an immediate surgical or interventional radiology procedure; c. Tracheal surgery or sternotomy during the previous 15 days;d. Serious facial trauma or facial surgery during the previous 15 days;e. Deep venous thrombosis treated for less than 2 days; f. Cardiac pacemaker inserted in the last 2 days;g. Unstable spine, femur, or pelvic fractures;h. Mean arterial pressure lower than 65 mm Hg;i. Pregnant women; j. Single anterior chest tube with air leaks. 2. Respiratory reason 1. Inhaled nitric oxide (NOi) or almitrine bismesylate use before inclusion;b. Use of extracorporeal membrane oxygenation (ECMO) before inclusion. 3. Clinical context a. Lung transplantation;b. Burns on more than 20 % of the body surface;c. Chronic respiratory failure requiring oxygen therapy or non-invasive ventilation(NIV);d. Underlying disease with a life expectancy of less than one year;e. NIV delivered for more than 24 hours before inclusion. 4. Other non-inclusion criteria a. End-of-life decision before inclusion;b. Inclusion in another research protocol in the previous 30 days with mortality as the main end-point;c. Prone positioning before inclusion;d. Subject deprived of freedom, minor, subject under a legal protective measure;e. Opposition from next of kin. Suspension criteria The criteria for suspension of participation are as follows: 1.Poor compliance of investigators or patients;2.Occurrence of serious adverse events (AEs), complications, or fatal physiological changes;3.Voluntary withdrawal;4.Incomplete data; Primary outcome measures: a.CURB-65 Score for Pneumonia Severity;b.The changes in inflammation and coagulation indicators: C-reactive protein, procalcitonin, and d-dimer;c.Chest x-ray changes;d.Mortality rate after 28 days;e.The time of mechanical ventilation, total duration of ICU stay, hospitalization, and antibiotic use;f.The time of bacterial cultures becoming negative;g.Daily sputum drainage. The statistical analysis will be performed using SAS software version 9.4 (SAS Institute, Cary, NC, USA). If the lower limit of the 95 % confidence interval is larger than a clinically meaningful difference, therapeutic effects of the experimental group are deemed to be clinically and statistically better than those of the control group. Two-sided tests will be performed for all the other statistical analyses. Cochran-Mantel-Haenszel χ2 tests or Fisher's exact tests will be used for comparison of categorical outcomes. Continuous outcomes will be analyzed by using Student's t test. p values ˂0.05 are considered to indicate statistical significance.

Interventions

  • Behavioral: Placed in prone position for at least 16 consecutive hours a day.
    • Patients assigned to the prone group had to be turned within the first hour following randomization. They were placed in prone position for at least 16 consecutive hours. Patients assigned to the control group had to be turned within the first hour following randomization. They were placed in supine position for at least 16 consecutive hours.

Arms, Groups and Cohorts

  • Experimental: The prone group
    • Patients assigned to the prone group had to be turned within the first hour following randomization. They were placed in prone position for at least 16 consecutive hours.
  • No Intervention: The supine group
    • Patients assigned to the supine group had to be turned within the first hour following randomization. They were placed in supine position for at least 16 consecutive hours.

Clinical Trial Outcome Measures

Primary Measures

  • The changes in C-reactive protein
    • Time Frame: On the tenth day after hospitalization
    • Use C-reactive protein to assess the patient’s lung infection status
  • The changes in procalcitonin
    • Time Frame: On the tenth day after hospitalization
    • Use procalcitonin to assess the patient’s lung infection status
  • The changes in d-dimer
    • Time Frame: On the tenth day after hospitalization
    • Use d-dimer to assess the patient’s lung infection status
  • Chest x-ray changes
    • Time Frame: On the tenth day after hospitalization
    • Use Chest x-ray to assess the patient’s lung infection status
  • Mortality rate after 28 days
    • Time Frame: 28 days after admission
    • Calculate patient 28-day mortality
  • The time of total duration of ICU stay
    • Time Frame: 28 day
    • Calculate The time of total duration of ICU stay
  • The time of mechanical ventilation
    • Time Frame: 28 day
    • Calculate The time of mechanical ventilation
  • mortality
    • Time Frame: 28 day
    • Using the Kaplan-Meier method to analyze the differences in mortality between the two groups within 28 days
  • The time of antibiotic use
    • Time Frame: 28 day
    • Calculate the time of antibiotic use
  • The time of bacterial cultures becoming negative
    • Time Frame: 28 day
    • Calculate the time of bacterial cultures becoming negative
  • Daily sputum drainage
    • Time Frame: On the tenth day after hospitalization
    • Calculate daily sputum drainage

Participating in This Clinical Trial

Inclusion Criteria

  • Age ≥18 years and ≤75 years, male or female – Weight ≥40 kg and ≤100 kg – Meet the diagnostic criteria for SP – Need invasive mechanical ventilation – Provide signed informed consent Exclusion Criteria:

  • Contraindication for prone positioning:a. Intracranial pressure >30 mm Hg or cerebral perfusion pressure <60 mmHg;b. Massive hemoptysis requiring an immediate surgical or interventional radiology procedure; c. Tracheal surgery or sternotomy during the previous 15 days;d. Serious facial trauma or facial surgery during the previous 15 days;e. Deep venous thrombosis treated for less than 2 days; f. Cardiac pacemaker inserted in the last 2 days;g. Unstable spine, femur, or pelvic fractures;h. Mean arterial pressure lower than 65 mm Hg;i. Pregnant women; j. Single anterior chest tube with air leaks. – Respiratory reason:a. Inhaled nitric oxide (NOi) or almitrine bismesylate use before inclusion;b. Use of extracorporeal membrane oxygenation (ECMO) before inclusion. – Clinical context:a. Lung transplantation;b. Burns on more than 20 % of the body surface;c. Chronic respiratory failure requiring oxygen therapy or non-invasive ventilation(NIV);d. Underlying disease with a life expectancy of less than one year;e. NIV delivered for more than 24 hours before inclusion. – Other noninclusion criteria :a. End-of-life decision before inclusion;b. Inclusion in another research protocol in the previous 30 days with mortality as the main end-point;c. Prone positioning before inclusion;d. Subject deprived of freedom, minor, subject under a legal protective measure;e. Opposition from next of kin.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 75 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Xiangya Hospital of Central South University
  • Collaborator
    • National Natural Science Foundation of China
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Pinhua Pan, Doctor, Study Director, Xiangya Hospital of Central South University
  • Overall Contact(s)
    • Lin, master, +86 15211013273, linfengyu2212@126.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.